Anti-BATF2, clone PCRP-BATF2-2B9

0.2 mg/ml in 1X PBS with 0.1 mg/ml BSA (US sourced), 0.05% sodium azide. Predicted to enable DNA-binding transcription factor activity, RNA polymerase II-specific and RNA polymerase II cis-regulatory region sequence-specific DNA binding activity. Predicted to be involved in defense response to protozoan, myeloid dendritic cell differentiation, and regulation of transcription by RNA polymerase II. Predicted to be part of chromatin. Predicted to be active in nucleus. This antibody recognizes a transcription factor involved in differentiation of CD8+ thymic dendritic cells. BATF2 has been implicated in breast cancer, malignant glioma and metastatis melanoma progression. Protein function: AP-1 family transcription factor that controls the differentiation of lineage-specific cells in the immune system. Following infection, participates in the differentiation of CD8(+) thymic conventional dendritic cells in the immune system. Acts via the formation of a heterodimer with JUN family proteins that recognizes and binds DNA sequence 5'-TGA[CG]TCA-3' and regulates expression of target genes. Selectively suppresses CCN1 transcription and hence blocks the downstream cell proliferation signals produced by CCN1 and inhibits CCN1-induced anchorage-independent growth and invasion in several cancer types, such as breast cancer, malignant glioma and metastatic melanoma. Possibly acts by interfering with AP-1 binding to CCN1 promoter. [The UniProt Consortium]